XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 4 - Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | 4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2025 |  |  | 2024 |
Leasehold improvements |  | $ | 2,519 |  |  | $ | 2,519 |
Laboratory equipment |  |  | 1,522 |  |  |  | 1,342 |
Furniture, fixtures and equipment |  |  | 966 |  |  |  | 966 |
Software |  |  | 283 |  |  |  | 272 |
Construction in progress |  |  | 46 |  |  |  | 29 |
Total property and equipment |  |  | 5,336 |  |  |  | 5,128 |
Less: Accumulated depreciation and amortization |  |  | (4,281 | ) |  |  | (3,968 | )
Total property and equipment, net |  | $ | 1,055 |  |  | $ | 1,160 |
Depreciation expense was $0.1 million for each of the three-months ended September 30, 2025 and 2024, and $0.3 million and $0.4 million for the nine-months ended September 30, 2025 and 2024, respectively. Intangible Assets, Net Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company’s NPS technology for biomedical applications acquired from Old Dominion University Research Foundation (“ODURF”), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets straight-line over an estimated useful life of 12 years. Intangible assets, net consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2025 |  |  | 2024 |
Acquired patents and licenses |  | $ | 8,005 |  |  | $ | 7,985 |
Less: Accumulated amortization |  |  | (7,264 | ) |  |  | (6,765 | )
Total intangible assets, net |  | $ | 741 |  |  | $ | 1,220 |
A schedule of the amortization of intangible assets for the remainder of 2025 and the succeeding final year is as follows (in thousands):
Years ending December 31: |  |  |  |
2025 (remaining 3 months) |  | $ | 166 |
2026 |  |  | 575 |
Total |  | $ | 741 |
Accrued Expenses Accrued expenses consisted of the following (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2025 |  |  | 2024 |
Compensation expense |  | $ | 3,588 |  |  | $ | 4,097 |
Clinical trial fees and costs |  |  | 953 |  |  |  | 284 |
Professional fees |  |  | 311 |  |  |  | 564 |
Legal settlement |  |  | — |  |  |  | 1,196 |
Severance |  |  | — |  |  |  | 698 |
Other |  |  | 351 |  |  |  | 188 |
Total accrued expenses |  | $ | 5,203 |  |  | $ | 7,027 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration